Median Technologies and PASREL-Imagerie to deliver imaging biomarkers for oncology drugs

The association aims to develop and implement smart imaging biomarkers to better understand the Mechanism of Action (MOA) of oncology drugs and collect more evidence of efficiency in early phase clinical trials

Median Technologies (ALMDT) and PASREL-Imagerie has announced the signing of an agreement to deliver imaging biomarkers for the development of new oncology drugs in the era of precision medicine. By leveraging its expertise in medical imaging, PASREL-Imagerie will bring its know-how and support to Median in the implementation of advanced imaging biomarkers for early phase oncology trials.

Whereas oncology clinical trials today rely primarily on relatively standard imaging assessments, the ability to implement advanced imaging biomarkers – including molecular imaging – specifically linked to the drug’s mechanism of action would help better understand the biological effect of each drug and collect additional evidence of efficiency during the early phases of clinical trials. The resulting knowledge would enable the biopharma industry to develop new drugs more effectively, while making the drug development cycle safer and shorter.

Nicolas Dano, COO iCRO, Median Technologies mentioned, “The agreement signed with PASREL-Imagerie aims to implement relevant and smart imaging biomarkers to assess new drug mechanisms of action and provide preliminary efficacy insights in early phase clinical trials. For us, this ability will be a unique point of differentiation compared to imaging vendors providing only classical imaging readouts. Through the association, Median will strengthen its superior expertise in medical imaging technologies with a scientific approach paving the way for fruitful discussions with translational and biomarker scientists as well as medical directors involved in the early phases of drug development. This agreement clearly demonstrates Median’s commitment to supporting the rise of precision medicine.”

Vincent Lebon, Director, PASREL-Imagerie and Department Chief, CEA said, “This alliance with Median Technologies, a key player in imaging for clinical trials, strengthens PASREL-Imagerie in its mission to support pharmaceutical industry by promoting its scientific expertise and its technology platforms for medical imaging” mentioned. We have here a synergy between two major players of the drug development value chain to accelerate and derisk medical innovation for patient benefit.”